Cephalosporin Market, By spectrum of antimicrobial activity (First, Second, Third, Fourth, and Fifth Generation), By Formulation (Oral and Injection), By Types (Prescription and OTC Drugs), By Application (Sexually Transmitted Disease, Respiratory Tract Infection, Skin Infection, Ear Infection, and Urinary Tract Infection), By Route of Administration, By Distribution Channel, and By Geography (EU, NA, APAC, LATAM, and MEA) Analysis, Size, Share, Trends, & Forecast from 2021-2027
REPORT HIGHLIGHT
The global Cephalosporin market was valued at USD 12.6 billion by 2019, growing with 4.8% CAGR during the forecast period, 2021-2027.
Cephalosporins are a broad group of antibiotics obtained from the mold Acremonium (formerly known as Cephalosporium). Cephalosporins are bactericidal and work in a comparable way to penicillins. They bind to and obstruct the activity of enzymes accountable for producing peptidoglycan, an essential bacterial cell wall component. They are termed broad-spectrum antibiotics because they are effective against a wide range of bacteria.
According to FDA, the cephalosporin class of drugs is essential in treating human diseases, such as pneumonia, skin and tissue infections, pelvic inflammatory disease, and other conditions.
Market Dynamics
The surge in the incidence of the population suffering from tonsillitis, pneumonia, bronchitis, and gonorrhea promotes market growth. Moreover, the rise in R&D activities to develop highly efficient & safe drugs, the rise in combination therapies, and increasing product launches coupled with rising approvals are the few factors propelling the growth. For instance, in May 2019, Sihuan Pharmaceutical Holdings Group Ltd., one of the largest cardio-cerebral vascular drug manufacturers in China, got its grant approval for “non-PVC solid-liquid double chamber bag for ceftazidime with sodium chloride injection, a third-generation cephalosporin.
Rising demand for antibacterial drugs further drives the growth of the global cephalosporin market. However, the side effects associated with these antibiotics, antibiotic resistance to cephalosporin, indefinite regulatory reforms are projected to impede the cephalosporin growth. On the other side, the discovery of advanced prospect molecules and the launch of innovative combination therapies to treat antibiotic-resistant microbial infections are likely to offer remunerative opportunities for the players.
Spectrum of Antimicrobial Activity Takeaway
Depending upon the spectrum of antimicrobial activity, the global business is categorized into first generation, second generation, third generation, fourth generation, and fifth generation. Among all, the third generation category occupied a lion’s share in 2019 and anticipated to witness the remarkable growth during the analysis period, owing to the high broader spectrum of activity which is used for the treatment of Gram-negative bacillary meningitis. Furthermore, fifth-generation cephalosporins are projected to witness the highest growth in the prediction period.
Formulation Takeaway
In terms of formulation, the worldwide industry is categorized into oral and injection. The oral formulations are further bifurcated into tablets, capsules, and liquids. Injection-based formulations are the most preferred drug administration route due to quick drug delivery and high bioavailability. However, liquid formulations are also gaining traction in the market because of the notable advantages offered by them, such as effective dispensing of the drug; masking the unpleasant taste of certain other ingredients; oxidation, or microbial activity; easy swallowing for young or elderly.
Types Takeaway
By type, the cephalosporin industry is classified into Over-the-counter (OTC) drugs and prescription drugs. OTC products are expanding at an impressive growth rate over the forecast timeframe. Major industry trends such as Rx to OTC switch by pharmaceutical manufacturers, the rising tendency of people towards self-medication in emerging regions, and cost-saving advantage to citizens in Latin America and Asia-Pacific regions are strongly driving the regional as well as global market.
The increasing patent expiration rates result in switching from Rx to OTC by the companies as a counter-strategy. According to the Consumer Healthcare Products Association, in the U.S., approximately 106 ingredients, dosage strengths, and indications have undergone a switch from Rx to OTC status, translating to approximately 700 OTC products in the market.
Route of Administration Takeaway
Based on the route of administration, the worldwide industry is classified into oral and injection. The injection route has occupied a remarkable share in 2019 and is projected to grow at a considerable CAGR during the timeframe. The high growth of this market segment is attributed to the rising prevalence of chronic diseases, faster onset of action than other dosage forms like tablets and liquids as the medication enters the bloodstream immediately
Application Takeaway
In terms of application, the worldwide industry is categorized into sexually transmitted diseases, respiratory tract infection, skin infection, ear infection, urinary tract infection, and others (acute abdomen infection, meningitis, and pelvic infection). The respiratory tract infection segment generated the maximum revenue in 2019 and is foreseen to maintain its global dominance throughout the prediction period, as cephalosporins are used to treat both lower & upper respiratory tract infections.
According to the reports published by WHO in 2019, influenza leads to respiratory tract infections in 5–15% of the population and severe illness in 3–5 million people every year. Respiratory syncytial virus (RSV) is the most common cause of acute respiratory infection in children, causing almost 34 million episodes annually. Also, the sexually transmitted disease (STD) segment is projected to witness the highest CAGR owing to the growing STD’s.
Distribution channels Takeaway
The worldwide industry is classified into online pharmacies, hospital pharmacies, and retail pharmacies in terms of distribution channels. The hospital pharmacies segment tends to dominate the market share during the outlook period. The growth is acknowledged majorly due to the growing count of patients admitted to hospitals because of the increasing prevalence of respiratory diseases and sexually transmitted infections.
The hospital pharmacies segment also focuses on preserving the standard of products related to this cancer for both out-patients and in-patients. The growing awareness about NSCLC and the developing healthcare infrastructures also aids in propelling hospital pharmacy growth with maximum profits.
Regional Takeaway
Regionally, the overall industry is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. North America is considered to be the most attractive market due to the rising prevalence of infectious diseases. For instance, according to the National Center for Health Statistics, the number of deaths due to pneumonia in the U.S. for the year 2017 is 49,157. Also, the number of emergency department visits with infectious and parasitic diseases as the primary diagnosis in the U.S. is around 4.1 million, showing lucrative opportunities for cephalosporin manufacturers.
On the flip side, Asia Pacific is projected to be the fastest-growing segment for the market. Developing countries such as India and China expect growth in such therapeutic drugs, accounting for the increasing diagnosis of pneumonia, sexually transmitted diseases, and tuberculosis. According to the reports published by MedIndia, about 6% of the adult population in India are affected by sexually transmitted diseases every year.
COVID-19 Impact
The emergence of the COVID-19 pandemic brought the world together to a standstill. However, the market for antibiotics, including cephalosporins, has seen a surge in the global market. In the research study, published in Clinical Infectious Diseases, researchers studied at data on more than 1,700 hospitalized coronavirus affected patients treated at 38 Michigan hospitals from March 13 to June 18 and observed that more than half received initial antibiotic therapy, with antibiotic treatment as high as 84% in some hospitals. But only a small fraction of those cases had bacterial co-infections. Subjects are being treated by various antibiotics globally, which are showing lucrative opportunities for the manufacturers.
Key Vendor Takeaway
Baxter International, Astellas, Abbott, Allergan Plc., Merck & Co. Inc., F.Hoffman-La Roche, Bristol-Myers Squibb, Lupin, GlaxoSmithKline, Basilea Pharmaceutical, Novartis AG, Pfizer, Inc., Sanofi, Teva Pharmaceutical Industries Ltd. among others.
The principal players are actively adopting various strategies such as acquisition, geographical expansion, development of new and efficient therapeutics, etc. to maintain their position in the market. Also, the companies are involved in the strategic development of new products, such as in 2017, Shionogi & Co. Ltd collaborated with F. Hoffmann-La Roche Ltd for the development and commercialization of baloxavir marboxi.
The market size and forecast for each segment and sub-segments has been considered as below:
- Historical Year – 2016 to 2018
- Base Year – 2019
- Estimated Year – 2020
- Projected Year – 2021 to 2027
TARGET AUDIENCE
- Traders, Distributors, and Suppliers
- Manufacturers
- Government and Regional Agencies
- Research Organizations
- Consultants
- Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CEPHALOSPORIN MARKET KEY PLAYERS
- FBaxter International
- Astellas
- Abbott
- Allergan Plc.
- Basilea Pharmaceutica Ltd.
- Bristol-Myers Squibb Company
- Hoffman-La Roche ltd.
- GlaxoSmithKline plc.
- Lupin Limited
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
GLOBAL CEPHALOSPORIN MARKET BY SPECTRUM OF ANTIMICROBIAL ACTIVITY
- First Generation
- Second Generation
- Third Generation
- Fourth Generation
- Fifth Generation
GLOBAL CEPHALOSPORIN MARKET BY FORMULATION
- Oral
- Tablets
- Capsules
- Liquid
- Injection
GLOBAL CEPHALOSPORIN MARKET BY TYPES
- Prescription Drugs
- OTC Drugs
GLOBAL CEPHALOSPORIN MARKET BY ROUTE OF ADMINISTRATION
- Injection
- Oral
GLOBAL CEPHALOSPORIN MARKET BY APPLICATION
- Sexually Transmitted Disease
- Respiratory Tract Infection
- Skin Infection
- Ear Infection
- Urinary Tract Infection
- Others (Acute Abdomen Infection, Meningitis, and Pelvic infection)
GLOBAL CEPHALOSPORIN MARKET BY FORMULATION
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
GLOBAL CEPHALOSPORIN MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Singapore
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Rest of MEA
TABLE OF CONTENT
1. CEPHALOSPORIN MARKET OVERVIEW
1.1. Study Scope
2. EXECUTIVE SUMMARY
2.1. Market Snippet
2.1.1. Market Snippet by Spectrum of Antimicrobial Activity
2.1.2. Market Snippet by Formulation
2.1.3. Market Snippet by Type
2.1.4. Market Snippet by Route of Administration
2.1.5. Market Snippet by Application
2.1.6. Market Snippet by Distribution Channel
2.1.7. Market Snippet by Region
2.2. Competitive Insights
3. CEPHALOSPORIN KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. CEPHALOSPORIN INDUSTRY STUDY
4.1. Porter’s Five Forces Analysis
4.2. Marketing Strategy Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. CEPHALOSPORIN MARKET: COVID-19 IMPACT ANALYSIS
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. CEPHALOSPORIN MARKET LANDSCAPE
6.1. Market Share Analysis, 2019
6.2. Key Innovators Analysis
6.3. Breakdown Data, by Key Manufacturer
6.3.1. Established Players’ Analysis
6.3.2. Emerging Players’ Analysis
7. CEPHALOSPORIN MARKET – BY SPECTRUM OF ANTI-MICROBIAL ACTIVITY
7.1. Overview
7.1.1. Segment Share Analysis, By Spectrum of Anti-microbial activity, 2020 & 2027 (%)
7.2. First generation
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.3. Second generation
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.4. Third generation
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.5. Fourth generation
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
7.6. Fifth generation
7.6.1. Overview
7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8. CEPHALOSPORIN MARKET – BY FORMULATION
8.1. Overview
8.1.1. Segment Share Analysis, By Formulation, 2020 & 2027 (%)
8.2. Oral
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.2.3. Tablets
8.2.3.1. Overview
8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.2.4. Capsules
8.2.4.1. Overview
8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.2.5. Liquids
8.2.5.1. Overview
8.2.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
8.3. Injection
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9. CEPHALOSPORIN MARKET – BY TYPE
9.1. Overview
9.1.1. Segment Share Analysis, By Type, 2020 & 2027 (%)
9.2. Prescription drugs
9.2.1. Overview
9.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
9.3. OTC drugs
9.3.1. Overview
9.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10. CEPHALOSPORIN MARKET – BY ROUTE OF ADMINISTRATION
10.1. Overview
10.1.1. Segment Share Analysis, By Route of Administration, 2020 & 2027 (%)
10.2. Oral
10.2.1. Overview
10.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
10.3. Injection
10.3.1. Overview
10.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11. CEPHALOSPORIN MARKET – BY APPLICATION
11.1. Overview
11.1.1. Segment Share Analysis, By Application, 2020 & 2027 (%)
11.2. Sexually Transmitted Disease
11.2.1. Overview
11.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.3. Sexually Transmitted Disease
11.3.1. Overview
11.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.4. Respiratory Tract Infection
11.4.1. Overview
11.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.5. Skin Infection
11.5.1. Overview
11.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.6. Urinary Tract Infection
11.6.1. Overview
11.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.7. Ear Infection
11.7.1. Overview
11.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
11.8. Others (Acute Abdomen Infection, Meningitis, and Pelvic infection)
11.8.1. Overview
11.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
12. CEPHALOSPORIN MARKET – BY DISTRIBUTION CHANNEL
12.1. Overview
12.1.1. Segment Share Analysis, By Distribution Channel, 2020 & 2027 (%)
12.2. Hospital Pharmacies
12.2.1. Overview
12.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
12.3. Online Pharmacies
12.3.1. Overview
12.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
12.4. Retail Pharmacies
12.4.1. Overview
12.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13. CEPHALOSPORIN MARKET– BY GEOGRAPHY
13.1. Introduction
13.1.1. Segment Share Analysis, By Geography, 2020 & 2027 (%)
13.2. North America
13.2.1. Overview
13.2.2. Key Manufacturers in North America
13.2.3. North America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
13.2.4. North America Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.2.5. North America Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.2.6. North America Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.2.7. North America Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.2.8. North America Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.2.9. North America Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.2.10. U.S.
13.2.10.1. Overview
13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.2.10.3. U.S. Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.2.10.4. U.S. Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.2.10.5. U.S. Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.2.10.6. U.S. Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.2.10.7. U.S. Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.2.10.8. U.S. Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.2.11. Canada
13.2.11.1. Overview
13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.2.11.3. Canada Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.2.11.4. Canada Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.2.11.5. Canada Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.2.11.6. Canada Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.2.11.7. Canada Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.2.11.8. Canada Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.3. Europe
13.3.1. Overview
13.3.2. Key Manufacturers in North America
13.3.3. Europe Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
13.3.4. Europe Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.3.5. Europe Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.3.6. Europe Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.3.7. Europe Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.3.8. Europe Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.3.9. Europe Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.3.10. Germany
13.3.10.1. Overview
13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.3.10.3. Germany Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.3.10.4. Germany Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.3.10.5. Germany Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.3.10.6. Germany Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.3.10.7. Germany Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.3.10.8. Germany Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.3.11. Italy
13.3.11.1. Overview
13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.3.11.3. Italy Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.3.11.4. Italy Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.3.11.5. Italy Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.3.11.6. Italy Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.3.11.7. Italy Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.3.11.8. Italy Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.3.12. United Kingdom
13.3.12.1. Overview
13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.3.12.3. United Kingdom Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.3.12.4. United Kingdom Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.3.12.5. United Kingdom Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.3.12.6. United Kingdom Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.3.12.7. United Kingdom Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.3.12.8. United Kingdom Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.3.13. France
13.3.13.1. Overview
13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.3.13.3. France Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.3.13.4. France Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.3.13.5. France Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.3.13.6. France Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.3.13.7. France Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.3.13.8. France Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.3.14. Rest of Europe
13.3.14.1. Overview
13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.3.14.3. Rest of Europe Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.3.14.4. Rest of Europe Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.3.14.5. Rest of Europe Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.3.14.6. Rest of Europe Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.3.14.7. Rest of Europe Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.3.14.8. Rest of Europe Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.4. Asia Pacific (APAC)
13.4.1. Overview
13.4.2. Key Manufacturers in Asia Pacific
13.4.3. Asia Pacific Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
13.4.4. Asia Pacific Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.4.5. Asia Pacific Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.4.6. Asia Pacific Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.4.7. Asia Pacific Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.4.8. Asia Pacific Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.4.9. Asia Pacific Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.4.10. India
13.4.10.1. Overview
13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.4.10.3. India Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.4.10.4. India Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.4.10.5. India Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.4.10.6. India Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.4.10.7. India Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.4.10.8. India Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.4.11. China
13.4.11.1. Overview
13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.4.11.3. China Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.4.11.4. China Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.4.11.5. China Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.4.11.6. China Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.4.11.7. China Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.4.11.8. China Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.4.12. Japan
13.4.12.1. Overview
13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.4.12.3. Japan Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.4.12.4. Japan Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.4.12.5. Japan Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.4.12.6. Japan Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.4.12.7. Japan Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.4.12.8. Japan Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.4.13. South Korea
13.4.13.1. Overview
13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.4.13.3. South Korea Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.4.13.4. South Korea Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.4.13.5. South Korea Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.4.13.6. South Korea Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.4.13.7. South Korea Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.4.13.8. South Korea Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.4.14. Rest of APAC
13.4.14.1. Overview
13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.4.14.3. Rest of APAC Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.4.14.4. Rest of APAC Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.4.14.5. Rest of APAC Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.4.14.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.4.14.7. Rest of APAC Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.4.14.8. Rest of APAC Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.5. Latin America
13.5.1. Overview
13.5.2. Key Manufacturers in Latin America
13.5.3. Latin America Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
13.5.4. Latin America Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.5.5. Latin America Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.5.6. Latin America Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.5.7. Latin America Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.5.8. Latin America Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.5.9. Latin America Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.5.10. Brazil
13.5.10.1. Overview
13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.5.10.3. Brazil Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.5.10.4. Brazil Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.5.10.5. Brazil Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.5.10.6. Brazil Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.5.10.7. Brazil Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.5.10.8. Brazil Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.5.11. Mexico
13.5.11.1. Overview
13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.5.11.3. Mexico Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.5.11.4. Mexico Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.5.11.5. Mexico Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.5.11.6. Mexico Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.5.11.7. Mexico Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.5.11.8. Mexico Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.5.12. Argentina
13.5.12.1. Overview
13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.5.12.3. Argentina Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.5.12.4. Argentina Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.5.12.5. Argentina Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.5.12.6. Argentina Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.5.12.7. Argentina Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.5.12.8. Argentina Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.5.13. Rest of LATAM
13.5.13.1. Overview
13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.5.13.3. Rest of LATAM Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.5.13.4. Rest of LATAM Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.5.13.5. Rest of LATAM Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.5.13.7. Rest of LATAM Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.5.13.8. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.6. Middle East and Africa
13.6.1. Overview
13.6.2. Key Manufacturers in Middle East and Africa
13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2016 – 2027 (US$ Million)
13.6.4. Middle East and Africa Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.6.5. Middle East and Africa Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.6.6. Middle East and Africa Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.6.8. Middle East and Africa Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.6.9. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.6.10. Saudi Arabia
13.6.10.1. Overview
13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.6.10.3. Saudi Arabia Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.6.10.4. Saudi Arabia Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.6.10.5. Saudi Arabia Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.6.10.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.6.10.7. Saudi Arabia Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.6.10.8. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
13.6.11. United Arab Emirates
13.6.11.1. Overview
13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2016 – 2027, (US$ Million)
13.6.11.3. United Arab Emirates Market Size and Forecast, By Spectrum of Anti-microbial activity, 2016 – 2027 (US$ Million)
13.6.11.4. United Arab Emirates Market Size and Forecast, By Formulation, 2016 – 2027 (US$ Million)
13.6.11.5. United Arab Emirates Market Size and Forecast, By Types, 2016 – 2027 (US$ Million)
13.6.11.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2016 – 2027 (US$ Million)
13.6.11.7. United Arab Emirates Market Size and Forecast, By Application, 2016 – 2027 (US$ Million)
13.6.11.8. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2016 – 2027 (US$ Million)
14. KEY VENDOR ANALYSIS
14.1. Competitive Dashboard
14.2. Company Profiles
14.2.1. Baxter International
14.2.1.1. Company Snapshot
14.2.1.2. Financial Performance
14.2.1.3. Product Benchmarking
14.2.1.4. Strategic Initiatives
14.2.2. Astellas
14.2.3. Abbott
14.2.4. Allergan Plc.
14.2.5. Basilea Pharmaceutical Ltd.
14.2.6. Bristol-Myers Squibb Company
14.2.7. F.Hoffman-La Roche ltd.
14.2.8. GlaxoSmithKline plc.
14.2.9. Lupin Limited
14.2.10. Merck & Co. Inc.
14.2.11. Novartis International AG
14.2.12. Pfizer Inc.
14.2.13. Sanofi
14.2.14. Teva Pharmaceutical Industries Ltd
15. 360 DEGREE ANALYSTVIEW
16. APPENDIX
16.1. Research Methodology
16.2. References
16.3. Abbreviations
16.4. Disclaimer
16.5. Contact Us
List of Tables
TABLE List of data sources
TABLE Market drivers; Impact Analysis
TABLE Market restraints; Impact Analysis
TABLE Cephalosporin market: Spectrum of Anti-microbial activity Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Spectrum of Anti-microbial activity
TABLE Global Cephalosporin market, by Spectrum of Anti-microbial activity 2016-2027 (USD Million)
TABLE Cephalosporin market: Formulation Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Formulation
TABLE Global Cephalosporin market, by Formulation 2016-2027 (USD Million)
TABLE Cephalosporin market:Types Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Types
TABLE Global Cephalosporin market, by Types 2016-2027 (USD Million)
TABLE Cephalosporin market: Route of Administration Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Route of Administration
TABLE Global Cephalosporin market, by Route of Administration 2016-2027 (USD Million)
TABLE Cephalosporin market: Application Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Application
TABLE Global Cephalosporin market, by Application 2016-2027 (USD Million)
TABLE Cephalosporin market: Distribution Channel Snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
TABLE Global Cephalosporin market, by Distribution Channel 2016-2027 (USD Million)
TABLE Cephalosporin market: Regional snapshot (2019)
TABLE Segment Dashboard; Definition and Scope, by Region
TABLE Global Cephalosporin market, by Region 2016-2027 (USD Million)
TABLE North America Cephalosporin market, by Country, 2016-2027 (USD Million)
TABLE North America Cephalosporin market, by Spectrum of Anti-microbial activity, 2016-2027 (USD Million)
TABLE North America Cephalosporin market, by Formulation, 2016-2027 (USD Million)
TABLE North America Cephalosporin market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Europe Cephalosporin market, by Country, 2016-2027 (USD Million)
TABLE Europe Cephalosporin market, by Spectrum of Anti-microbial activity, 2016-2027 (USD Million)
TABLE Europe Cephalosporin market, by Formulation, 2016-2027 (USD Million)
TABLE Europe Cephalosporin market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Asia Pacific Cephalosporin market, by Country, 2016-2027 (USD Million)
TABLE Asia Pacific Cephalosporin market, by Spectrum of Anti-microbial activity, 2016-2027 (USD Million)
TABLE Asia Pacific Cephalosporin market, by Formulation, 2016-2027 (USD Million)
TABLE Asia Pacific Cephalosporin market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Latin America Cephalosporin market, by Country, 2016-2027 (USD Million)
TABLE Latin America Cephalosporin market, by Spectrum of Anti-microbial activity, 2016-2027 (USD Million)
TABLE Latin America Cephalosporin market, by Formulation, 2016-2027 (USD Million)
TABLE Latin America Cephalosporin market, by Distribution Channel, 2016-2027 (USD Million)
TABLE Middle East and Africa Cephalosporin market, by Country, 2016-2027 (USD Million)
TABLE Middle East and Africa Cephalosporin market, by Spectrum of Anti-microbial activity, 2016-2027 (USD Million)
TABLE Middle East and Africa Cephalosporin market, by Spectrum of Anti-microbial activity, 2016-2027 (USD Million)
TABLE Middle East and Africa Cephalosporin market, by Spectrum of Anti-microbial activity, 2016-2027 (USD Million)
List of Figures
FIGURE Cephalosporin market segmentation
FIGURE Market research methodology
FIGURE Value chain analysis
FIGURE Porter’s Five Forces Analysis
FIGURE Market Attractiveness Analysis
FIGURE COVID-19 Impact Analysis
FIGURE Pre & Post COVID-19 Impact Comparision Study
FIGURE Competitive Landscape; Key company market share analysis, 2019
FIGURE Spectrum of Anti-microbial activity segment market share analysis, 2020 & 2027
FIGURE Spectrum of Anti-microbial activity segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE First Generation market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Second Generation market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Third Generation market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Fourth Generation market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Fifth Generation market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Formulation segment market share analysis, 2020 & 2027
FIGURE Formulation segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Oral market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Injection market size forecast and trend analysis, 2016 to 2027 (USD Million)
Types segment market share analysis, 2020 & 2027
FIGURE Types segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Prescription drugs forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE OTC drugs market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Route of Administration segment market share analysis, 2020 & 2027
FIGURE Route of Administration segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Oral market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Injection market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Application segment market share analysis, 2020 & 2027
FIGURE Application segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Sexually Transmitted Disease market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Respiratory Tract Infection market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Skin Infection market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Ear Infection market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Urinary Tract Infectionmarket size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Others (Acute Abdomen Infection, Meningitis, and Pelvic infection) market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Distribution Channel segment market share analysis, 2020 & 2027
FIGURE Distribution Channel segment market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Hospital Pharmacies market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Online Pharmacies market size forecast and trend analysis, 2016 to 2027 (USD Million)
FIGURE Retail Pharmacies market size forecast and trend analysis, 2016
